Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 31 | 2023 | 1535 | 3.120 |
Why?
|
| Alzheimer Disease | 32 | 2024 | 2063 | 3.020 |
Why?
|
| Cognitive Dysfunction | 17 | 2024 | 1020 | 2.180 |
Why?
|
| Hospitalization | 5 | 2019 | 289 | 1.750 |
Why?
|
| Cognition | 20 | 2023 | 1288 | 1.610 |
Why?
|
| Dementia | 11 | 2024 | 527 | 1.610 |
Why?
|
| Aged, 80 and over | 54 | 2024 | 4660 | 1.570 |
Why?
|
| Health Literacy | 7 | 2018 | 105 | 1.480 |
Why?
|
| Independent Living | 12 | 2022 | 307 | 1.330 |
Why?
|
| Aged | 60 | 2024 | 8703 | 1.280 |
Why?
|
| Female | 62 | 2023 | 14347 | 1.130 |
Why?
|
| Male | 63 | 2023 | 13980 | 1.100 |
Why?
|
| Activities of Daily Living | 10 | 2022 | 522 | 1.080 |
Why?
|
| Humans | 77 | 2024 | 25964 | 0.940 |
Why?
|
| Cohort Studies | 20 | 2022 | 1815 | 0.920 |
Why?
|
| Brain | 15 | 2022 | 1642 | 0.890 |
Why?
|
| Decision Making | 12 | 2016 | 222 | 0.880 |
Why?
|
| Economics | 3 | 2018 | 17 | 0.840 |
Why?
|
| Longitudinal Studies | 18 | 2023 | 1338 | 0.770 |
Why?
|
| DNA-Binding Proteins | 5 | 2022 | 254 | 0.750 |
Why?
|
| Work | 1 | 2020 | 7 | 0.730 |
Why?
|
| Social Behavior | 2 | 2011 | 64 | 0.730 |
Why?
|
| Women | 1 | 2020 | 14 | 0.720 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2021 | 109 | 0.650 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2019 | 17 | 0.640 |
Why?
|
| Emergencies | 1 | 2019 | 33 | 0.630 |
Why?
|
| Cognition Disorders | 6 | 2016 | 986 | 0.580 |
Why?
|
| Social Participation | 2 | 2022 | 11 | 0.570 |
Why?
|
| Interpersonal Relations | 3 | 2014 | 96 | 0.560 |
Why?
|
| Neuropsychological Tests | 15 | 2021 | 1223 | 0.560 |
Why?
|
| Information Literacy | 2 | 2014 | 9 | 0.550 |
Why?
|
| Biomarkers | 2 | 2020 | 547 | 0.550 |
Why?
|
| Social Environment | 3 | 2011 | 78 | 0.530 |
Why?
|
| Risk Assessment | 1 | 2019 | 621 | 0.530 |
Why?
|
| United States | 9 | 2024 | 1971 | 0.520 |
Why?
|
| Motor Activity | 3 | 2013 | 313 | 0.500 |
Why?
|
| Delay Discounting | 1 | 2015 | 24 | 0.480 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 42 | 0.480 |
Why?
|
| Caregivers | 10 | 2008 | 145 | 0.460 |
Why?
|
| Trust | 1 | 2014 | 13 | 0.450 |
Why?
|
| Fraud | 1 | 2014 | 21 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 162 | 0.430 |
Why?
|
| Mental Health | 2 | 2014 | 105 | 0.420 |
Why?
|
| Age Factors | 8 | 2020 | 742 | 0.420 |
Why?
|
| Medicare | 4 | 2024 | 114 | 0.410 |
Why?
|
| Educational Status | 6 | 2020 | 281 | 0.390 |
Why?
|
| Association | 1 | 2011 | 7 | 0.390 |
Why?
|
| Residence Characteristics | 6 | 2016 | 208 | 0.370 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 97 | 0.370 |
Why?
|
| Mobility Limitation | 2 | 2012 | 94 | 0.370 |
Why?
|
| Cerebral Infarction | 1 | 2012 | 150 | 0.370 |
Why?
|
| Risk Factors | 11 | 2022 | 2240 | 0.360 |
Why?
|
| Diet, Mediterranean | 2 | 2023 | 81 | 0.360 |
Why?
|
| Risk | 4 | 2015 | 197 | 0.350 |
Why?
|
| Middle Aged | 20 | 2019 | 8507 | 0.320 |
Why?
|
| Loneliness | 3 | 2023 | 55 | 0.320 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1710 | 0.310 |
Why?
|
| Memory | 6 | 2018 | 300 | 0.300 |
Why?
|
| Prospective Studies | 6 | 2019 | 1646 | 0.290 |
Why?
|
| Apolipoprotein E4 | 4 | 2022 | 244 | 0.290 |
Why?
|
| Sex Factors | 7 | 2020 | 442 | 0.290 |
Why?
|
| Autopsy | 5 | 2021 | 338 | 0.290 |
Why?
|
| Brain Infarction | 2 | 2018 | 74 | 0.280 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 326 | 0.270 |
Why?
|
| Quality of Life | 3 | 2012 | 609 | 0.260 |
Why?
|
| Mental Competency | 4 | 2008 | 9 | 0.250 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 250 | 0.250 |
Why?
|
| Social Isolation | 2 | 2023 | 22 | 0.250 |
Why?
|
| Chicago | 7 | 2021 | 841 | 0.240 |
Why?
|
| Mental Status and Dementia Tests | 3 | 2020 | 69 | 0.240 |
Why?
|
| Genotype | 2 | 2018 | 335 | 0.230 |
Why?
|
| Income | 3 | 2022 | 72 | 0.230 |
Why?
|
| Family | 2 | 2020 | 93 | 0.230 |
Why?
|
| Stress, Psychological | 3 | 2016 | 211 | 0.210 |
Why?
|
| Neuroimaging | 2 | 2021 | 133 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 304 | 0.200 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 22 | 0.190 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 138 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 215 | 0.190 |
Why?
|
| Disease Progression | 4 | 2020 | 685 | 0.190 |
Why?
|
| Depression | 3 | 2015 | 407 | 0.190 |
Why?
|
| Politics | 3 | 2008 | 10 | 0.180 |
Why?
|
| Patient Participation | 4 | 2008 | 49 | 0.180 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 852 | 0.180 |
Why?
|
| Financing, Personal | 3 | 2018 | 19 | 0.180 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.180 |
Why?
|
| Employment | 1 | 2020 | 40 | 0.180 |
Why?
|
| Cognitive Reserve | 1 | 2021 | 39 | 0.180 |
Why?
|
| Personality | 1 | 2021 | 53 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2021 | 64 | 0.170 |
Why?
|
| Socioeconomic Factors | 2 | 2018 | 287 | 0.170 |
Why?
|
| Arteriolosclerosis | 2 | 2021 | 78 | 0.170 |
Why?
|
| Awareness | 1 | 2020 | 36 | 0.170 |
Why?
|
| Cognitive Aging | 1 | 2020 | 79 | 0.160 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 318 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2020 | 165 | 0.160 |
Why?
|
| Prevalence | 3 | 2012 | 433 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2011 | 287 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 5 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 7 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 370 | 0.160 |
Why?
|
| Models, Neurological | 1 | 2018 | 24 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 43 | 0.150 |
Why?
|
| Research Subjects | 2 | 2008 | 11 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 311 | 0.150 |
Why?
|
| Blood Glucose | 1 | 2018 | 99 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 115 | 0.150 |
Why?
|
| Neural Pathways | 1 | 2018 | 71 | 0.150 |
Why?
|
| Neurofibrillary Tangles | 4 | 2022 | 191 | 0.150 |
Why?
|
| Regression Analysis | 2 | 2015 | 252 | 0.150 |
Why?
|
| Hospital Mortality | 1 | 2018 | 130 | 0.150 |
Why?
|
| Learning | 2 | 2016 | 63 | 0.140 |
Why?
|
| White Matter | 2 | 2016 | 141 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 451 | 0.140 |
Why?
|
| Informed Consent | 2 | 2008 | 19 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 132 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 137 | 0.140 |
Why?
|
| Ambulatory Care | 1 | 2017 | 68 | 0.140 |
Why?
|
| Adult | 6 | 2022 | 7349 | 0.140 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2016 | 12 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2016 | 10 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 173 | 0.130 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2016 | 17 | 0.130 |
Why?
|
| Intelligence | 1 | 2016 | 20 | 0.130 |
Why?
|
| Incidence | 3 | 2016 | 706 | 0.130 |
Why?
|
| Interview, Psychological | 2 | 2008 | 34 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 55 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 27 | 0.130 |
Why?
|
| Alleles | 2 | 2018 | 201 | 0.130 |
Why?
|
| Crime Victims | 1 | 2016 | 25 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2017 | 416 | 0.130 |
Why?
|
| Amyloid | 3 | 2021 | 57 | 0.120 |
Why?
|
| Health Behavior | 2 | 2014 | 153 | 0.120 |
Why?
|
| Time Factors | 3 | 2014 | 1361 | 0.120 |
Why?
|
| Psychological Tests | 1 | 2015 | 45 | 0.120 |
Why?
|
| Multilingualism | 1 | 2014 | 11 | 0.120 |
Why?
|
| Poverty | 1 | 2015 | 96 | 0.120 |
Why?
|
| Minority Groups | 1 | 2015 | 70 | 0.120 |
Why?
|
| Racism | 1 | 2015 | 32 | 0.120 |
Why?
|
| Music | 1 | 2014 | 19 | 0.120 |
Why?
|
| Neoplasms | 1 | 2017 | 219 | 0.110 |
Why?
|
| Social Support | 2 | 2015 | 179 | 0.110 |
Why?
|
| tau Proteins | 3 | 2022 | 225 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 161 | 0.110 |
Why?
|
| Odds Ratio | 4 | 2018 | 259 | 0.110 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 218 | 0.110 |
Why?
|
| Automobile Driving | 1 | 2012 | 10 | 0.100 |
Why?
|
| Actigraphy | 1 | 2012 | 85 | 0.100 |
Why?
|
| Neprilysin | 1 | 2012 | 11 | 0.100 |
Why?
|
| Disabled Persons | 1 | 2013 | 124 | 0.100 |
Why?
|
| Lewy Bodies | 3 | 2018 | 193 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 131 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2011 | 43 | 0.090 |
Why?
|
| Environmental Health | 1 | 2010 | 8 | 0.090 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 15 | 0.090 |
Why?
|
| Health Status | 2 | 2012 | 211 | 0.090 |
Why?
|
| Lead Poisoning, Nervous System, Adult | 1 | 2010 | 1 | 0.090 |
Why?
|
| Lead | 1 | 2010 | 2 | 0.090 |
Why?
|
| Phobic Disorders | 1 | 2010 | 64 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2010 | 17 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 2010 | 16 | 0.090 |
Why?
|
| Urban Population | 1 | 2011 | 143 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2005 | 929 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 411 | 0.080 |
Why?
|
| Urban Health | 1 | 2008 | 21 | 0.080 |
Why?
|
| Third-Party Consent | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2008 | 3 | 0.080 |
Why?
|
| Assisted Living Facilities | 1 | 2008 | 3 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1066 | 0.080 |
Why?
|
| Attitude | 1 | 2008 | 30 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 44 | 0.070 |
Why?
|
| Nursing Homes | 1 | 2008 | 33 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 145 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 43 | 0.070 |
Why?
|
| Selegiline | 1 | 2005 | 4 | 0.060 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 10 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2018 | 547 | 0.060 |
Why?
|
| Mood Disorders | 1 | 2005 | 25 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 37 | 0.060 |
Why?
|
| Self Report | 2 | 2016 | 204 | 0.060 |
Why?
|
| Civil Rights | 1 | 2004 | 3 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 333 | 0.060 |
Why?
|
| Illinois | 2 | 2015 | 226 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2015 | 110 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 19 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 37 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2022 | 8 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 30 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 11 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 66 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 22 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1140 | 0.050 |
Why?
|
| Logistic Models | 2 | 2018 | 360 | 0.050 |
Why?
|
| Motor Skills | 1 | 2021 | 52 | 0.050 |
Why?
|
| Individuality | 1 | 2021 | 22 | 0.050 |
Why?
|
| Neuroticism | 1 | 2021 | 32 | 0.050 |
Why?
|
| Southeastern United States | 1 | 2020 | 9 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2020 | 62 | 0.040 |
Why?
|
| Baltimore | 2 | 2011 | 10 | 0.040 |
Why?
|
| Religion | 1 | 2019 | 40 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 7 | 0.040 |
Why?
|
| Heterozygote | 1 | 2018 | 91 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 261 | 0.040 |
Why?
|
| Neuropathology | 1 | 2018 | 83 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2017 | 24 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2008 | 94 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 301 | 0.030 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 24 | 0.030 |
Why?
|
| Critical Care | 1 | 2018 | 190 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2017 | 141 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 82 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 51 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 85 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 66 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 200 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 90 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 16 | 0.030 |
Why?
|
| Demography | 1 | 2015 | 71 | 0.030 |
Why?
|
| Cities | 1 | 2015 | 16 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 186 | 0.030 |
Why?
|
| Financial Management | 1 | 2015 | 24 | 0.030 |
Why?
|
| Life Change Events | 1 | 2014 | 31 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2016 | 115 | 0.030 |
Why?
|
| Empathy | 1 | 2014 | 38 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 67 | 0.030 |
Why?
|
| Language | 1 | 2014 | 62 | 0.030 |
Why?
|
| Spouses | 2 | 2005 | 25 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 568 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 9 | 0.030 |
Why?
|
| Licensure | 1 | 2012 | 9 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 13 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 22 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 22 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2012 | 15 | 0.020 |
Why?
|
| Environment | 1 | 2012 | 41 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 1280 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 104 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 54 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 253 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 238 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 264 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 109 | 0.020 |
Why?
|
| Data Collection | 1 | 2011 | 91 | 0.020 |
Why?
|
| Executive Function | 1 | 2011 | 113 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2010 | 41 | 0.020 |
Why?
|
| Organ Size | 1 | 2010 | 95 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 225 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 202 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 321 | 0.020 |
Why?
|
| Intermittent Claudication | 1 | 2008 | 3 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 3386 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2008 | 19 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 2008 | 18 | 0.020 |
Why?
|
| Simvastatin | 1 | 2008 | 5 | 0.020 |
Why?
|
| Observer Variation | 1 | 2008 | 93 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 105 | 0.020 |
Why?
|
| Health Surveys | 1 | 2008 | 84 | 0.020 |
Why?
|
| Social Class | 1 | 2008 | 63 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 132 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 749 | 0.020 |
Why?
|
| Tibia | 1 | 2010 | 256 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3292 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 134 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 485 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 304 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 23 | 0.020 |
Why?
|
| Judgment | 1 | 2005 | 8 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 45 | 0.020 |
Why?
|
| Nootropic Agents | 1 | 2005 | 13 | 0.020 |
Why?
|
| Stroke | 1 | 2008 | 254 | 0.020 |
Why?
|
| Policy Making | 1 | 2004 | 14 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2004 | 55 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2005 | 145 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 132 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 123 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2002 | 7 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 90 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 670 | 0.010 |
Why?
|